[18F]FP-R01-MG-F2 for Idiopathic Pulmonary Fibrosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Stanford University, Stanford, CAIdiopathic Pulmonary Fibrosis+2 More[18F]FP-R01-MG-F2 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial looked at using a new PET scan to detect three different diseases: idiopathic pulmonary fibrosis, primary sclerosing cholangitis, and coronavirus disease 2019.

Eligible Conditions
  • Idiopathic Pulmonary Fibrosis
  • Primary Sclerosing Cholangitis
  • Coronavirus Pneumonia

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: an estimated average of 2 hours

Hour 1
Time Activity Measurements
Hour 2
Incidence of Study Completion (Safety and Tolerability)
SUV max comparison : IPF versus Healthy Lung, PSC versus Healthy Liver, COVID19 versus Healthy Lung

Trial Safety

Trial Design

3 Treatment Groups

[18F]FP-R01-MG-F2 PET/CT in actively infected COVID19 Patients
1 of 3
[18F]FP-R01-MG-F2 PET/CT in PSC Patients
1 of 3
[18F]FP-R01-MG-F2 PET/CT in IPF Patients, Recovered COVID19 Patients, and Health...
1 of 3

Experimental Treatment

30 Total Participants · 3 Treatment Groups

Primary Treatment: [18F]FP-R01-MG-F2 · No Placebo Group · Phase < 1

[18F]FP-R01-MG-F2 PET/CT in actively infected COVID19 Patients
Drug
Experimental Group · 1 Intervention: [18F]FP-R01-MG-F2 · Intervention Types: Drug
[18F]FP-R01-MG-F2 PET/CT in PSC Patients
Drug
Experimental Group · 1 Intervention: [18F]FP-R01-MG-F2 · Intervention Types: Drug
[18F]FP-R01-MG-F2 PET/CT in IPF Patients, Recovered COVID19 Patients, and Healthy Volunteers
Drug
Experimental Group · 1 Intervention: [18F]FP-R01-MG-F2 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: an estimated average of 2 hours

Who is running the clinical trial?

Pliant Therapeutics, Inc.Industry Sponsor
5 Previous Clinical Trials
262 Total Patients Enrolled
3 Trials studying Idiopathic Pulmonary Fibrosis
144 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Stanford UniversityLead Sponsor
2,185 Previous Clinical Trials
35,092,531 Total Patients Enrolled
4 Trials studying Idiopathic Pulmonary Fibrosis
72 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Henry Guo, MD, PhD5.01 ReviewsStudy Director - Stanford University
Stanford University

Eligibility Criteria

Age 18+ · All Participants · 23 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to understand the treatment options and make an informed decision.
If you had COVID-19 in the past and have recovered, you can participate in Scanning Option A or Scanning Option B. If you currently have COVID-19 or have no evidence of past infection, you can participate in Scanning Option D.
You must undergo either Scanning Option A or Scanning Option B.
You must choose either Scanning Option A or Scanning Option B.
This is not a complete criterion. More information is needed to understand what "Scanning Option C" means.

Frequently Asked Questions

Does this clinical research currently have any open spots to enroll in?

"Affirmative. Evidence on clinicaltrials.gov reveals that this trial is now recruiting, with the first posting of the study taking place on November 8th 2017 and an update being made as recently as May 3rd 2022. 30 patients are expected to take part across 1 facility." - Anonymous Online Contributor

Unverified Answer

What is the current recruitment size for this experiment?

"Affirmative. The listing on clinicaltrials.gov attests to this research initiative's current recruitment of patients, which commenced on November 8th 2017 and was most recently revised on May 3rd 2022. 30 participants are planned to be enrolled at one particular medical site." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.